CA3095988A1 - Novel glp-1 analogues - Google Patents

Novel glp-1 analogues Download PDF

Info

Publication number
CA3095988A1
CA3095988A1 CA3095988A CA3095988A CA3095988A1 CA 3095988 A1 CA3095988 A1 CA 3095988A1 CA 3095988 A CA3095988 A CA 3095988A CA 3095988 A CA3095988 A CA 3095988A CA 3095988 A1 CA3095988 A1 CA 3095988A1
Authority
CA
Canada
Prior art keywords
amino
group
compound
moiety
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3095988A
Other languages
English (en)
French (fr)
Inventor
Rajamannar Thennati
Nishith Chaturvedi
Vinod Sampatrao BURADE
Pradeep Dinesh SHAHI
Muthukumaran Natarajan
Ravishankara Madavati NAGARAJA
Rishit Mansukhlal ZALAWADIA
Kunal PANDYA
Brijeshkumar PATEL
Dhiren Rameshchandra JOSHI
Krunal Harishbhai SONI
Abhishek Tiwari
Vipulkumar Shankarbhai PATEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industries Ltd
Original Assignee
Sun Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Ltd filed Critical Sun Pharmaceutical Industries Ltd
Publication of CA3095988A1 publication Critical patent/CA3095988A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transmission And Conversion Of Sensor Element Output (AREA)
CA3095988A 2018-04-05 2019-04-05 Novel glp-1 analogues Pending CA3095988A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
IN201821013109 2018-04-05
IN201821013109 2018-04-05
IN201821040468 2018-10-26
IN201821040468 2018-10-26
IN201821040474 2018-10-26
IN201821040474 2018-10-26
PCT/IB2019/052835 WO2019193576A1 (en) 2018-04-05 2019-04-05 Novel glp-1 analogues

Publications (1)

Publication Number Publication Date
CA3095988A1 true CA3095988A1 (en) 2019-10-10

Family

ID=66589592

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3095988A Pending CA3095988A1 (en) 2018-04-05 2019-04-05 Novel glp-1 analogues

Country Status (33)

Country Link
US (7) US11447535B2 (cg-RX-API-DMAC7.html)
EP (4) EP4740955A3 (cg-RX-API-DMAC7.html)
JP (3) JP7250814B2 (cg-RX-API-DMAC7.html)
KR (2) KR102801994B1 (cg-RX-API-DMAC7.html)
CN (3) CN112236444B (cg-RX-API-DMAC7.html)
AU (3) AU2019247936C1 (cg-RX-API-DMAC7.html)
BR (1) BR112020020419A2 (cg-RX-API-DMAC7.html)
CA (1) CA3095988A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020002574A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020012425A2 (cg-RX-API-DMAC7.html)
CY (1) CY1125528T1 (cg-RX-API-DMAC7.html)
DK (3) DK4122954T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP20070185A (cg-RX-API-DMAC7.html)
ES (2) ES2925678T3 (cg-RX-API-DMAC7.html)
FI (2) FI4364751T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20240749T1 (cg-RX-API-DMAC7.html)
HU (2) HUE067499T2 (cg-RX-API-DMAC7.html)
IL (1) IL277483B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20200251B1 (cg-RX-API-DMAC7.html)
LT (3) LT4364751T (cg-RX-API-DMAC7.html)
MX (2) MX2020010505A (cg-RX-API-DMAC7.html)
MY (1) MY202560A (cg-RX-API-DMAC7.html)
PE (1) PE20211417A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020551591A1 (cg-RX-API-DMAC7.html)
PL (2) PL3774862T3 (cg-RX-API-DMAC7.html)
PT (2) PT4122954T (cg-RX-API-DMAC7.html)
RS (2) RS65639B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202009467YA (cg-RX-API-DMAC7.html)
SI (2) SI4122954T1 (cg-RX-API-DMAC7.html)
SM (2) SMT202200352T1 (cg-RX-API-DMAC7.html)
UA (1) UA128210C2 (cg-RX-API-DMAC7.html)
WO (1) WO2019193576A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202306729B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202200352T1 (it) * 2018-04-05 2022-09-14 Sun Pharmaceutical Ind Ltd Analoghi del glp-1 innovativi
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
WO2020180534A1 (en) 2019-03-01 2020-09-10 President And Fellows Of Harvard College Methods and compositions for protein delivery
TW202216746A (zh) * 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 長效型glp-1/gip雙重促效劑
CN116171164A (zh) * 2020-10-17 2023-05-26 太阳医药工业有限公司 Glp-1/gip双重激动剂
CN114685646B (zh) * 2020-12-31 2023-04-07 厦门赛诺邦格生物科技股份有限公司 一种多肽侧链类似物的制备方法及其应用
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
CA3237751A1 (en) 2021-11-10 2023-05-19 Tyler Brown Ionic liquid compositions
CN115785249B (zh) * 2022-10-13 2023-07-21 江苏师范大学 一类glp-1类似物及其应用
EP4724472A2 (en) 2023-06-09 2026-04-15 Sun Pharmaceutical Industries Limited Glp-1/gip dual, glp-1/gcg dual and glp-1/gip/gcg triple receptor agonists
WO2024261580A1 (en) 2023-06-20 2024-12-26 Sun Pharmaceutical Industries Limited Glp-1 analog for use in the treatment of metabolic disorders
CN117756914B (zh) * 2023-12-15 2024-09-03 瀚晖制药有限公司 依柯胰岛素的制备方法
AU2025216394A1 (en) 2024-01-31 2026-07-16 Sun Pharmaceutical Industries Ltd. High level production of glp1 analogues

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
JP2002508162A (ja) 1998-02-27 2002-03-19 ノボ ノルディスク アクティーゼルスカブ N末端を短縮したglp−1誘導体
AU2610899A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally modified glp-1 derivatives
AU3247799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
EP1060191B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S Derivatives of glp-1 analogs
FR2777283B1 (fr) 1998-04-10 2000-11-24 Adir Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1137667B1 (en) 1998-12-07 2004-11-17 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Analogues of glp-1
DE60137876D1 (de) 2000-06-16 2009-04-16 Lilly Co Eli Analoge des Glucagon-ähnlichen Peptids-1
SI1724284T1 (sl) 2000-12-07 2009-12-31 Lilly Co Eli Glp-1 fuzijski proteini
AR038102A1 (es) 2002-01-08 2004-12-29 Lilly Co Eli Analogos extendidos de peptido 1 de tipo glucagon
WO2004037859A1 (ja) 2002-10-11 2004-05-06 Sanwa Kagaku Kenkyusho Co., Ltd. Glp-1誘導体及びその経粘膜吸収型製剤
WO2004078777A2 (en) 2003-03-04 2004-09-16 Biorexis Pharmaceutical Corporation Dipeptidyl-peptidase protected proteins
EP1633384B1 (en) 2003-05-15 2012-03-14 Trustees Of Tufts College Stable analogs of glp-1
EP1670515A2 (en) 2003-09-19 2006-06-21 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
EP1711523B1 (en) 2003-12-16 2012-10-10 Ipsen Pharma Analogues of glp-1
JP2008515856A (ja) 2004-10-07 2008-05-15 ノボ ノルディスク アクティーゼルスカブ 遅延性glp−1化合物
ES2484796T3 (es) * 2005-03-18 2014-08-12 Novo Nordisk A/S Compuestos de GLP-1 extendidos
TWI362392B (en) * 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
CA2607566A1 (en) 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
CA2621699A1 (en) 2005-09-08 2007-03-15 Trustees Of Tufts College Stabilized glp-1 analogs
RS51319B (sr) 2005-09-22 2010-12-31 Biocompatibles Uk Limited GLP-l (GLUKAGON-LIKE PEPTID-l) FUZIONI POLIPEPTIDI SA POVEĆANOM OTPORNOSTI NA PEPTIDAZE
US20100261637A1 (en) 2007-09-05 2010-10-14 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
WO2009058734A1 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
US20120329711A1 (en) 2009-12-16 2012-12-27 Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
WO2011134284A1 (zh) 2010-04-27 2011-11-03 浙江贝达药业有限公司 胰高血糖素样肽-1类似物及其应用
CN102203130B (zh) 2010-08-06 2014-06-25 贝达药业股份有限公司 Glp-1衍生物及其应用
JP6231386B2 (ja) 2010-11-09 2017-11-15 ノヴォ ノルディスク アー/エス リンカーを有する二重アシル化されたglp−1誘導体
AU2012241894B2 (en) 2011-04-12 2015-12-03 Novo Nordisk A/S Double-acylated GLP-1 derivatives
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
JP6126097B2 (ja) 2011-09-06 2017-05-10 ノヴォ ノルディスク アー/エス Glp−1誘導体
EP2578599A1 (en) 2011-10-07 2013-04-10 LanthioPep B.V. Cyclic analogs of GLP-1 and GLP-1 related peptides
EP2846823B1 (en) 2012-05-08 2019-12-04 Novo Nordisk A/S Double-acylated glp-1 derivatives
CN104411322B (zh) 2012-05-08 2017-05-24 诺和诺德股份有限公司 双酰化glp‑1衍生物
JP2015525226A (ja) 2012-06-14 2015-09-03 サノフイ エキセンディン−4ペプチドアナログ
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
TWI617574B (zh) 2012-12-11 2018-03-11 梅迪繆思有限公司 用於治療肥胖之升糖素與glp-1共促效劑
HUE035803T2 (en) 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
AU2014283221A1 (en) 2013-06-20 2015-12-03 Novo Nordisk A/S GLP-1 derivatives and uses thereof
US9738697B2 (en) 2013-06-23 2017-08-22 Wisconsin Alumni Research Foundation Alpha/beta-polypeptide analogs of glucagon-like peptide-1
JP6139712B2 (ja) 2013-07-04 2017-05-31 ノヴォ ノルディスク アー/エス Glp−1様ペプチドの誘導体及びその使用
CN105451776B (zh) 2013-08-15 2020-04-17 诺和诺德股份有限公司 Glp-1衍生物及其用途
AR098065A1 (es) * 2013-10-17 2016-04-27 Zealand Pharma As Análogos de glucagón acilados
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重glp-1/升糖素受體促效劑
WO2015086731A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
CA2933405A1 (en) 2013-12-13 2015-06-18 Medimmune Limited Protease-resistant peptides
JP6730278B2 (ja) 2014-11-27 2020-07-29 ノヴォ ノルディスク アー/エス Glp−1誘導体及びその使用
EP3233898A1 (en) 2014-12-17 2017-10-25 Novo Nordisk A/S Glp-1 derivatives and uses thereof
TWI726889B (zh) 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽
US10111932B2 (en) 2015-08-26 2018-10-30 Syracuse University Coagonists of glucagon-like peptide 1 receptor and neuropeptide Y2 receptor
WO2017149070A1 (en) 2016-03-03 2017-09-08 Novo Nordisk A/S Glp-1 derivatives and uses thereof
CA3025592A1 (en) 2016-06-09 2017-12-14 Medimmune Limited Protease-resistant mono-lipidated peptides
ES2828526T3 (es) 2016-11-07 2021-05-26 Novo Nordisk As Esteres activos DCHBS de compuestos PEG y sus usos
AR110301A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip
WO2018178796A1 (en) * 2017-03-27 2018-10-04 Sun Pharmaceutical Industries Limited Method for making kex1 protease sensitive polypeptides using yeast strain
PL3704143T3 (pl) 2018-03-09 2024-04-15 Fresenius Kabi Ipsum S.R.L. Chemo-enzymatyczna synteza liraglutydu, semaglutydu i glp-1
SMT202200352T1 (it) * 2018-04-05 2022-09-14 Sun Pharmaceutical Ind Ltd Analoghi del glp-1 innovativi

Also Published As

Publication number Publication date
AU2023203430B2 (en) 2025-07-03
US20220402992A1 (en) 2022-12-22
US20220402991A1 (en) 2022-12-22
IL277483B2 (en) 2026-05-01
EP4364751A3 (en) 2024-06-26
EP4122954B1 (en) 2024-04-03
ZA202306729B (en) 2024-03-27
RS63523B1 (sr) 2022-09-30
US20210206823A1 (en) 2021-07-08
CN120554480A (zh) 2025-08-29
US11485766B2 (en) 2022-11-01
IL277483A (en) 2020-11-30
EP4740955A3 (en) 2026-07-22
KR102801994B1 (ko) 2025-04-30
EP4364751B1 (en) 2026-06-03
LT3774862T (lt) 2022-09-12
SMT202200352T1 (it) 2022-09-14
MX2020010505A (es) 2021-01-15
HRP20240749T1 (hr) 2024-09-13
HUE067499T2 (hu) 2024-10-28
BR112020020419A2 (pt) 2021-01-19
US20240376175A1 (en) 2024-11-14
JP2023078367A (ja) 2023-06-06
CO2020012425A2 (es) 2020-12-21
EP4740955A2 (en) 2026-05-13
EP3774862B1 (en) 2022-06-08
JP2026075626A (ja) 2026-05-08
PL4122954T3 (pl) 2024-08-12
PH12020551591A1 (en) 2021-08-16
US11242373B2 (en) 2022-02-08
PT3774862T (pt) 2022-09-05
HRP20221054T1 (hr) 2022-11-11
AU2019247936B2 (en) 2023-03-02
PE20211417A1 (es) 2021-08-02
CN112236444A (zh) 2021-01-15
HUE060135T2 (hu) 2023-02-28
US11873328B2 (en) 2024-01-16
EP4364751A2 (en) 2024-05-08
US12421289B2 (en) 2025-09-23
JP7250814B2 (ja) 2023-04-03
PL3774862T3 (pl) 2022-10-03
AU2019247936A1 (en) 2020-10-15
UA128210C2 (uk) 2024-05-08
US20190309040A1 (en) 2019-10-10
SG11202009467YA (en) 2020-10-29
AU2025242190A1 (en) 2025-10-23
KR20250065720A (ko) 2025-05-13
EP4122954A1 (en) 2023-01-25
AU2023203430A1 (en) 2023-06-29
JP7863526B2 (ja) 2026-05-21
SI4122954T1 (sl) 2024-07-31
LT4364751T (lt) 2026-08-10
RS65639B1 (sr) 2024-07-31
IL277483B1 (en) 2026-01-01
FI4364751T3 (fi) 2026-07-15
US20200362007A1 (en) 2020-11-19
WO2019193576A1 (en) 2019-10-10
US20240199718A1 (en) 2024-06-20
KR20200141469A (ko) 2020-12-18
JOP20200251A1 (ar) 2020-10-04
ECSP20070185A (es) 2021-01-29
JP2021520346A (ja) 2021-08-19
ES2925678T3 (es) 2022-10-19
DK4364751T3 (da) 2026-06-29
NZ768446A (en) 2025-10-31
FI4122954T3 (fi) 2024-06-18
JOP20200251B1 (ar) 2024-04-18
KR102990055B1 (ko) 2026-07-14
CL2020002574A1 (es) 2021-06-04
US11447535B2 (en) 2022-09-20
LT4122954T (lt) 2024-06-25
SI3774862T1 (sl) 2022-10-28
CN112236444B (zh) 2025-09-19
DK3774862T3 (da) 2022-09-05
AU2019247936C1 (en) 2023-06-15
CY1125528T1 (el) 2026-02-25
SMT202400241T1 (it) 2024-07-09
MX2024007688A (es) 2024-07-09
ES2980707T3 (es) 2024-10-02
PT4122954T (pt) 2024-06-05
EP3774862A1 (en) 2021-02-17
US11866477B2 (en) 2024-01-09
MY202560A (en) 2024-05-08
DK4122954T3 (da) 2024-06-10
CN117964735A (zh) 2024-05-03

Similar Documents

Publication Publication Date Title
US11873328B2 (en) GLP-1 analogues
CN106928341B (zh) 定点单取代聚乙二醇化Exendin类似物及其制备方法
HK40103760A (en) Novel glp-1 analogues
HK40086836B (en) Novel glp-1 analogues
HK40086836A (en) Novel glp-1 analogues
HK40044876A (en) Novel glp-1 analogues
HK40044876B (en) Novel glp-1 analogues
EA049274B1 (ru) Новые аналоги glp-1

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240402

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST

Effective date: 20250226

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST

Effective date: 20250226

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250320

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250328

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250328

R17 Change to representative recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250822

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R17-R117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250822

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250822

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250924

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260123

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260203

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260203

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260203